We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
News

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
News

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. Afshin Safavi, Founder and Chief Scientific Officer at BioAgilytix Labs, said: “As a trusted partner to six of the top ten global pharmaceutical and biotech companies, it is vital that we broaden our technology offering and continue to deliver the highest quality bioanalysis possible. In the hands of our highly experienced scientists, the Gyros platform will allow BioAgilytix to continue to provide the quality data our customers have grown to expect, while also meeting growing capacity demands. Moreover, the nanoliter scale of the platform enables us to generate such data from small volumes of precious sample, maximizing the number of assays that can be performed.”
 
“Major biopharmaceutical companies are increasingly desiring that immunoassay testing be developed and completed using Gyrolab xP workstations due to its high precision, low sample volumes, and ease with which assays can be transferred,” commented Dan Calvo, CEO at Gyros. “We are delighted that BioAgilytix has adopted the Gyros platform and are confident it will enable them to continue to provide their customers with high quality bioanalysis.”
 
Gyros platform comprises Gyrolab workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.

Advertisement